Despite the need for improved specificity towards HER2, [52Mn]Mn-DOTAGA(anhydride)-trastuzumab demonstrates a favorable tumor-to-background ratio and relatively good tracer stability. The gene discussed is ERBB2; the disease is neoplasm.